Short Interest in Silexion Therapeutics Corp (NASDAQ:SLXN) Drops By 89.3%
by Sarita Garza · The Markets DailySilexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 16,557 shares, a decrease of 89.3% from the May 31st total of 154,973 shares. Based on an average trading volume of 233,740 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.1% of the company’s shares are short sold.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.
Check Out Our Latest Research Report on SLXN
Silexion Therapeutics Stock Up 0.7%
Shares of NASDAQ SLXN traded up $0.02 during midday trading on Friday, hitting $2.75. The stock had a trading volume of 32,999 shares, compared to its average volume of 207,813. The company has a market capitalization of $1.16 million, a price-to-earnings ratio of -0.03 and a beta of -0.32. Silexion Therapeutics has a 1-year low of $2.31 and a 1-year high of $223.60. The company has a fifty day moving average price of $5.20 and a 200 day moving average price of $13.74.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($12.90) by $12.05. On average, research analysts forecast that Silexion Therapeutics will post -45.5 EPS for the current year.
Silexion Therapeutics Company Profile
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.